"JMHO but if we replicate previous trial results of 55%  - 77%, market share and revenues will be even way higher."

No recent CVOT trial to my memory has exceeded 26% RRR for 3-point MACE. SUSTAIN 6 (Semaglutide) achieved 26% RRR in 3-point MACE due to effects on non-fatal MI and non-fatal stroke (no effect on CV death). Most CVOT trials fail, or if they do achieve their primary outcome have an RRR in the teens. If apabetalone even achieves 30% RRR for 3-point MACE, that will be unprecedented. Keep in mind that the 55% to 77% RRR numbers from the post-hoc analyses of apabetalone Phase 2 trials are for 5-point MACE, not the strict 3-point MACE.

BearDownAZ